Of the screened four genes (ALCAM, CD22, CASP1, and CISH), CD22 is a sialic acid-binding immunoglobulin-like lectin (Siglec) that is highly expressed on B cell lymphomas and is a validated target for antibody and nanoparticle-based therapeutics on non-Hodgkin lymphoma (39, 40). This evidence concerns the gene CD22 and non-Hodgkin lymphoma.